Published Literature | B²O Pharmaceutical Technology (Shanghai) Co., Ltd.

Published Papers

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population

2021/03

Accelerating Development of Benziamidazole-Class ProtonPump Inhibitors A Mechanism-Based PKPD Model toOptimize Study Design with Ilaprazole as a Case Drug

2021/02

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population

2021/01

Model-Guided Drug Discovery: Development History and Application Thinking

2021/04

Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1−4 by Virtual Bioequivalence Model

2022/12

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray

2022/07

The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers

2022/01

PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

2022/01

Related Publications

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically-Based Pharmacokinetic Model

Cao Y, Hu Y, Zhang J, et al.

Prediction of pharmacokinetic / pharmacodynamic properties of aldosterone synthase inhibitors at drug discovery stage using an artificial intelligence-physiologically based pharmacokinetic model.

Zhang M, Wu K, Long S, Jin X, Liu B.

Predicting Drug-Drug Interactions Involving Rifampicin Using a Semi-mechanistic Hepatic Compartmental Model.

Li J, Li X, Wu K, et al.

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.

Wu K, Li X, Zhou Z, et al.

Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling.

Zhang J, Wu K, Liu B, et al.

Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1-4 by Virtual Bioequivalence Model.

Zhang F, Wu X, Wu K, Yu M, Liu B, Wang H.

In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.

Zhang F, Zhou Y, Wu N, et al.

Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug.

Jia R, Zhang F, Wu N, et al.

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.

Zhang F, Jia R, Gao H, Wu X, Liu B, Wang H.

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray.

Wu X, Zhang F, Yu M, et al.

Quantifying Induction/ Inhibition Effects on Fuzuloparib Using a Physiologically Based Pharmaco-Kinetic (PBPK) model.

Li J, Wu K, Li X, Long S, Zhou Z, et al.

Predicting Fluconazole Drug-Drug Interactions Using a Physiologically-based Pharmacokinetic (PBPK) Model.

Li X, Wu K, Zhou Z, Jia R, Zhao Y, et al.

Published Papers

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population

Accelerating Development of Benziamidazole-Class ProtonPump Inhibitors A Mechanism-Based PKPD Model toOptimize Study Design with Ilaprazole as a Case Drug

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population

Model-Guided Drug Discovery: Development History and Application Thinking

Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1−4 by Virtual Bioequivalence Model

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray

The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers

PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

Related Publications

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically-Based Pharmacokinetic Model

Prediction of pharmacokinetic / pharmacodynamic properties of aldosterone synthase inhibitors at drug discovery stage using an artificial intelligence-physiologically based pharmacokinetic model.

Predicting Drug-Drug Interactions Involving Rifampicin Using a Semi-mechanistic Hepatic Compartmental Model.

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.

Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling.

Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1-4 by Virtual Bioequivalence Model.

In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.

Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug.

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray.

Quantifying Induction/ Inhibition Effects on Fuzuloparib Using a Physiologically Based Pharmaco-Kinetic (PBPK) model.

Predicting Fluconazole Drug-Drug Interactions Using a Physiologically-based Pharmacokinetic (PBPK) Model.

Contact Information